Orasure Technologies earnings date
Orasure Technologies (EP3) Q3 2026 Earnings Report
CH:EP3 Q3 2026 EPS Results
- Actual EPS
- -CHF 0.16
- Consensus EPS
- -CHF 0.17
- Beat/Miss
- Beat by +CHF 0.01
- One Year Ago EPS
- -CHF 0.16
CH:EP3 Q3 2026 Revenue Results
- Actual Revenue
- CHF 25.51M
- Expected Revenue
- CHF 25.59M
- Beat/Miss
- Missed by -CHF 76.76K
- YoY Revenue Growth
- +14.11%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/09/2026
- Time
- After Close
- Conference Call
- Monday, November 9, 2026
Orasure Technologies's next earnings date is estimated for March 2, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was broadly positive, reflecting a return to growth, strong performance in Diagnostic Products and Sample Management Solutions, gross margin expansion, lower operating spend, a debt-free balance sheet, and confidence in 2027 revenue acceleration. However, the company remains loss-making with negative operating cash flow, delayed cash flow breakeven, uncertain CT/NG regulatory timing, and delayed Ebola contracting catalysts. The highlights significantly outweighed the lowlights.
For the fourth quarter, OraSure expects revenue between $30 million and $32 million, representing year-over-year growth of approximately 12% to 20%, with gross margin in Q4 expected to be similar to or slightly below Q3 and OpEx expected to be similar to Q3 overall; full year 2026 revenue is expected between $119.5 million and $121.5 million, implying a full year growth rate between 3.8% and 5.6%, with 4.7% at the midpoint. The company now expects to reach cash flow from operations breakeven in the second half of 2027 and expects full year revenue growth to accelerate in 2027 compared with 2026, with additional insights to be provided on the fourth quarter earnings call; it also expects strong growth on a year-over-year basis in Q4 and expects that Ebola and Colli-Pee will be part of the acceleration of growth referred to for 2027.
- Return to Revenue GrowthOraSure delivered 2026 third-quarter revenue of $30.9 million, up 14% year over year and approximately 1% sequentially. Management characterized the quarter as another solid quarter of execution and a return to growth.
- Diagnostic Products GrowthDiagnostic products generated $16.8 million of Q3 revenue, representing 16% year-over-year growth. The increase was driven by higher international HIV revenue, stabilization in African markets, customer order timing, improved HCV performance supported by U.S. funding dynamics, and continued growth from Sickle SCAN.
- Sample Management Solutions GrowthSample Management Solutions revenue was $12.5 million in Q3, up 21% year over year. Growth was driven by key commercial customer growth and the timing of specific commercial orders. The portfolio also grew more than 20% both year over year and sequentially.
- Gross Margin ExpansionGAAP gross margin increased 173 basis points to 45.2% from 43.5% in the third quarter of last year. Non-GAAP gross margin increased to 45.9% from 44.2%. The improvement was driven by operational efficiencies and improved overhead absorption.
- Operating Expense ReductionR&D expense was $7.6 million, down $1.8 million sequentially as development-related spending tapered. G&A declined to $12.0 million, a $2.4 million reduction resulting from lower nonrecurring legal and professional service costs. Management said operating spend improved materially sequentially and expects Q4 OpEx to be similar to Q3 overall.
- Strong Balance SheetOraSure ended the quarter with zero debt and $148.2 million of total cash and cash equivalents.
- Ebola Test Authorization and Initial OrdersThe company received FDA emergency use authorization in July for OraQuick Ebola 2.0, which detects all four Ebola virus species known to cause human disease, including Bundibugyo. OraSure quickly fulfilled initial commercial orders following the authorization, and management said manufacturing capability is ready to serve the region's needs.
- Localized International Diagnostics StrategyOraSure launched local assembly in Uganda, where its partner is expanding access to HIV products and has potential to add Ebola and other products. Nigeria is the next planned market for the localized approach. Management said localization, partnerships and country-specific pathways are intended to expand access and diversify the international diagnostics business.
- Sickle SCAN ExpansionOraSure continues to support newborn sickle cell screening across Africa, where Africa CDC estimates that 300,000 to 400,000 babies are born with sickle cell disease each year. The company is using its international commercial infrastructure and partnerships, including a recently announced Nairobi partnership focused on scaling Sickle SCAN across community health centers.
- Strength in U.S. DiagnosticsU.S. Diagnostics delivered strong year-over-year growth, driven by strength in HCV and syphilis testing and continued underlying demand for HIV testing. Management highlighted the syndemic testing strategy, which combines rapid testing solutions for HIV, HCV and syphilis.
- Colli-Pee Dx Commercial LaunchFollowing FDA clearance in June, OraSure commercially launched the Colli-Pee Dx urine collection kit in the third quarter. Management said it was encouraged by initial sales and by the pipeline of potential customers evaluating self-collected urine workflows for STI testing.
- Continued Innovation InvestmentOraSure continues to invest in innovation, including early development of HPV testing as a potential future application for Colli-Pee in collaboration with leading global molecular diagnostic partners. The company also expects increased contributions from Colli-Pee, its NucleoPrecision chemistry and partnerships with IVD platform manufacturers.
- Fourth-Quarter and 2027 Revenue OutlookQ4 revenue guidance is $30 million to $32 million, representing approximately 12% to 20% year-over-year growth. Full-year 2026 revenue guidance is $119.5 million to $121.5 million, implying growth of 3.8% to 5.6%, with 4.7% at the midpoint. Management expects full-year revenue growth to accelerate in 2027 compared with 2026, driven by a combination of core business growth and new product launches.
- Improved Manufacturing EfficiencyManagement said consolidation and leveraging existing manufacturing capabilities are improving operational efficiency and overhead absorption. The company expects the absorption gains built during 2026 to continue improving as the business scales.
- Strategic Investment and Partnership PositionOraSure continues to evaluate organic and inorganic opportunities that could accelerate profitable growth in high-value markets and leverage existing capabilities. Through its existing investment in Sapphiros, OraSure remains a minority investor in Onvaro, formed by the combination of Sapphiros and binx health, while its strategic agreements with Sapphiros remain in place.
CH:EP3 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 02, 2027 | 2026 (Q4) | -0.14- | -0.22 | ― | ― |
| Nov 09, 2026 | 2026 (Q3) | -0.17-0.16 | -0.16 | 0.00% (+0.00) | |
| Aug 05, 2026 | 2026 (Q2) | -0.220.07 | -0.21 | 134.62% (+0.29) | |
| May 06, 2026 | 2026 (Q1) | -0.19-0.26 | -0.17 | -52.38% (-0.09) | |
| Feb 25, 2026 | 2025 (Q4) | -0.17-0.22 | -0.12 | -92.86% (-0.11) | |
| Nov 05, 2025 | 2025 (Q3) | -0.16-0.16 | -0.05 | -216.67% (-0.11) | |
| Aug 05, 2025 | 2025 (Q2) | -0.17-0.21 | -0.01 | -2500.00% (-0.21) | |
| May 07, 2025 | 2025 (Q1) | -0.13-0.17 | -0.04 | -320.00% (-0.13) | |
| Feb 25, 2025 | 2024 (Q4) | -0.05-0.12 | 0.22 | -151.85% (-0.34) | |
| Nov 06, 2024 | 2024 (Q3) | -0.06-0.05 | 0.12 | -140.00% (-0.17) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
